Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7,938,059
-
Total 13F shares
-
16,206,423
-
Share change
-
-369,389
-
Total reported value
-
$85,728,624
-
Put/Call ratio
-
15%
-
Price per share
-
$5.29
-
Number of holders
-
50
-
Value change
-
-$2,790,984
-
Number of buys
-
14
-
Number of sells
-
34
Institutional Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q3 2021
As of 30 Sep 2021,
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) was held by
50 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
16,206,423 shares.
The largest 10 holders included
Ikarian Capital, LLC, Bain Capital Life Sciences Investors, LLC, AIGH Capital Management LLC, ORBIMED ADVISORS LLC, VANGUARD GROUP INC, BVF INC/IL, Altium Capital Management LP, Sio Capital Management, LLC, AXA S.A., and Monashee Investment Management LLC.
This page lists
50
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.